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1. Introduction 
Current statistics from the World Health Organization, Heart and Stroke Foundation of 
Canada, and the American Heart Association show that cardiovascular disease remains a 
leading cause of death (Heart and Stroke Foundation of Canada [HSFO], 2011; Roger et al., 
2011; World Health Organization [WHO], 2011). Innovative and integrative approaches 
aimed at understanding and treating heart disease are needed. In this chapter we introduce 
a novel field of investigation called cardiovascular circadian proteomics. This approach is 
based on the application of high throughput proteomic technologies for discovery of 
molecular processes in cardiovascular tissues over the 24-hour day/night cycles. Time is a 
crucial but frequently overlooked factor affecting our physiology in health and disease. 
Circadian cardiovascular proteomics offers considerable promise to advance our 
understanding of heart disease (indeed disease in general), and opens new avenues for 
treatment of patients clinically.  
2. The circadian system and its importance to cardiovascular physiology 
Life on earth is subject to a 24-hour day/night (circadian or diurnal) cycle. Circadian 
systems have evolved to allow physiological and behavioural processes to be synchronous 
with this cycle – mammals are adapted to sleep either during the day or at night.  Circadian 
clocks allow us to entrain to environmental cues and hence anticipate the differing 
physiologic and behavioural demands of daily events.  In mammals, the system is organized 
as a hierarchy with multiple oscillators, as has been well reviewed (Hastings et al., 2003; 
Rajaratnam & Arendt, 2001; Reppert & Weaver, 2001, 2002). At the top is the hypothalamic 
suprachiasmatic nucleus (SCN), a brain region functioning as a master rhythmic regulator 
(Figure 1A).  The SCN integrates light information received from the eyes to coordinate 
clocks throughout the body. There are additional circadian regulatory systems such as the 
food entrainable clock (Storch & Weitz, 2009) which we are just now beginning to 
understand, but are beyond the scope of this review. We observe the output of the entrained 
clocks as daily physiologic rhythms, many of which are crucial to the cardiovascular system, 
such as the cyclic variation in heart rate (HR) and blood pressure (BP). Daily HR and BP 
follow the diurnal variation of our autonomic nervous system and increase around wake-
time to help sustain cardiac output, then decrease during the period of vagal dominance at 
night and in the early morning (Guo & Stein, 2003; Imai et al., 1990).  
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Circadian rhythms also underlie the timing of onset of adverse cardiovascular events. The 
incidence of myocardial infarction in humans peaks in the morning (~6:00A.M.-12:00 noon) 
(Cohen et al., 1997; Goldberg et al., 1990; Muller et al., 1985). A similar pattern is observed in 
the incidences of sudden cardiac death (Muller et al., 1989; Willich et al., 1987), ventricular 
tachyarrhythmia (Eksik et al., 2007; Tofler et al., 1995), and rupture of aortic aneurysms 
(Manfredini et al., 2004; Mehta et al., 2002; Sumiyoshi et al., 2002). Precursor risk factors 
such as vasomotor tone, platelet aggregability, and other factors involved in thrombosis or 
thrombolysis also exhibit daily rhythms (Andrews et al., 1996; Angleton et al., 1989; 
Decousus et al., 1985; Maemura et al., 2000; Otto et al., 2004). Recent studies link timing of 
onset of adverse cardiac events  with a circadian clock mechanism, reviewed in (Durgan & 
Young, 2010; Martino & Sole, 2009; Sole & Martino, 2009).  
Proteins involved in the molecular clock mechanism have been identified in the last 10+ 
years, and daily oscillations of this mechanism in peripheral tissues, including the 
myocardium, are believed to be primarily combination of self-sustaining cycling along with 
neural/hormonal cues from the SCN. It is illustrated in Figure 1B and described in many 
excellent reviews (Hastings et al., 2003; Reddy et al., 2005; Roenneberg & Merrow, 2005). 
Though we focus here on protein cycling, it is important to note that there are post-
translational rhythms as well, such as phosphorylation. Though beyond the scope of this 
review the reader is directed to several examples (Akashi et al., 2002; Lowrey et al., 2000; 
Iitaka et al., 2005; Yin et al., 2006). 
In the following sections, we describe how application of the circadian concepts, in 
combination with state-of-the-art proteomics, provides significant new opportunities for 
understanding disease physiology, for biomarker discovery, and helping patients 
clinically. 
3. Discovery of the circadian heart proteome 
Our laboratory is focussed on discovering the circadian heart proteome both in normal 
tissue and in disease. Initial studies are done using murine models of cardiovascular 
disease, and later are translated clinically. Here we describe the circadian proteome in 
normal C57Bl/6 mouse heart, and in our well-established murine model of heart disease 
termed pressure-overload induced cardiac hypertrophy by Transverse Aortic Constriction 
(TAC). To induce heart disease, eight week old male mice were entrained to a 12:12 light 
(L): dark (D) cycle and administered TAC surgery where a ligature was placed distal to 
the third bifurcation of aorta (Figure 2A). In sham operated animals the surgical 
procedure was identical, but the ligature was not tightened. (Figure 2A). For proteomic 
studies, heart tissues were collected one week later (as the heart remodels), at six time-
points 4 hours apart over the 24-hour L:D cycle (Figure 2B). The proteome was analyzed 
by two-dimensional difference in gel electrophoresis (2D-DIGE) and mass spectrometry 
(MS). Figure 2B illustrates the experimental workflow design. The technical details are 
described below. 
3.1 Protein purification and labelling 
The cytoplasmic soluble proteome was purified from either TAC or sham left ventricular 
heart tissue. Cardiac tissue was immersed in 600 l ice-cold cell lysis buffer (10 mM Tris pH 
8, 8 M Urea, 4% w/v 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
(CHAPS), and protease inhibitors). The lysis buffer helps to solubilize, denature, and  
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A) Light activates dedicated retinal receptors and signals the hypothalamic suprachiasmatic nucleus 
(SCN). The SCN is a master body clock, and orchestrates physiologic and molecular rhythms in 
peripheral organs including the heart. Rhythms relevant to the heart include the daily cycling of heart 
rate and blood pressure, also timing of onset of acute cardiac events such as myocardial infarction.  
B) The molecular clock mechanism is dependent upon oscillating levels of proteins that interact via a  
24-hour autoregulatory feedback. On the positive arm BMAL1 and CLOCK combine as heterodimers 
and bind to E-box elements upstream in the coding regions of other core clock elements, PERIOD and 
CRYPTOCHROME. These are phosphorylated by CASEIN KINASE 1 EPSILON (or DELTA), form 
heterodimers, then translocate to the nucleus.  There, they bind to the same E-box elements thus 
negatively regulating their own expression. The positive loop also initiates production of RETINOIC 
ACID-RELATED ORPHAN NUCLEAR RECEPTOR ALPHA resulting in its inhibition, and completion 
of the 24-hour cycle. CAPITAL=Proteins; italic=mRNA. 
Fig. 1. The Circadian System. 
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disaggregate proteins. Cell disruption was carried out using a Potter-Elvehjem tissue 
grinder. Following centrifugation the supernatant was collected and proteins were 
quantified by Bradford assay.  
Prior to protein separation, 50 g of each sample was labelled with CyDyes (Cy3/Cy5), and 
an internal control was pooled from both lysates and labelled with Cy2 (Figure 2B). To 
account for any bias due to preferential binding of CyDyes, a dye swap approach was also 
done in a separate experiment, so that the samples were alternatively labelled with the 
reciprocal dye. CyDyes form a covalent bond between their NHS ester reactive group and 
epsilon amino group of protein’s lysine residues. The labelling reaction does not cause a 
significant change in isolectric point because lysine carries an intrinsic +1 charge at neutral 
or acidic pH, which is replaced by CyDye’s +1 charge. CyDyes were added so that there was 
a stoichiometric excess of proteins and thus only 1-5% of lysines were labelled. The reaction 
was carried out for 30 minutes in the dark, and then quenched with 10 mM lysine.  
3.2 First dimension isoelectric focussing 
Proteins were separated in the first dimension by isoelectric focusing (IEF) based on our 
standard operating protocol (Hobson et al., 2007). In the experiment shown here (Figure 3) 
we used nonlinear 13 cm immobilized pH gradient (IPG) strips pH 3 – 10 (GE Healthcare). 
The CyDye labelled samples were combined and mixed with rehydration buffer (8 M urea, 
2% w/v CHAPS, Dithiothreitol (DTT), 0.5% v/v carrier pharmalytes). Then, samples in 
rehydration buffer were applied at the bottom of the IPG strip holder. The strip was put on 
top of the sample solution and covered with paraffin oil to prevent crystallization of urea, 
water loss and carbon dioxide dissolving at the alkaline end of the strip. IEF was done using 
an Ettan IPGphore unit. The initial step was active rehydration, allowing proteins to slowly 
enter the strip along its whole length under the influence of a small current (30 V for 10 h). 
The next series of steps were 500 V step and hold for 2 h, 1000 V gradient for 1 h, 8000 V 
gradient for 2.5 h, 8000 V step and hold for 16000 V h, 500 V step and hold for 2 h. The result 
was that proteins migrated to a position in accordance with their isoelectric point.  
3.3 Second dimension electrophoresis 
For the second dimension, the sample containing IPG strips were equilibrated with sodium 
dodecyl sulfate (SDS) running buffer (75 mM Tris (pH 8.8), 6 M Urea, 30% v/v Glycerol and 
2% w/v SDS). DTT was added to reduce disulfide bonds, and iodoacetamide (IAA) to 
alkylate thiol groups what prevented disulfide bonds from reforming. After equilibration 
the IPG strip was applied directly on top of a large format 16 X 14 cm 12% acrylamide gel. 
Agarose was poured on top of the strip to prevent air from getting underneath and to hold 
strip in place. Molecular markers were applied 4 cm from the positive end of the strip. The 
proteins were then separated vertically according to their molecular weight by SDS-
polyacrylamide gel electrophoresis (PAGE) on a DALT 6 electrophoresis unit at 20 0C,  
6 W/ gel for 18 h.  
3.4 Protein detection and bioinformatics analysis  
After 2D-DIGE, the relative abundance of proteins from the TAC heart disease versus sham 
protein lysates was detected using a high resolution fluorescent scanner Typhoon 9410 (GE 
Healthcare). The excitation/emission wavelengths for the CyDyes were as follows: Cy2,  
480 nm/530 nm (blue), Cy3, 540 nm/590 nm (green) and Cy5, 620 nm/680 nm (red). Images  
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A) Heart disease model. Pressure overload cardiac hypertrophy is induced by transverse aortic 
constriction (TAC). A ligature is placed distal to the third bifurcation of aorta. Sham animals undergo the 
same procedure except the ligature is not tightened. B) Two-dimensional difference in gel electrophoresis 
(2D-DIGE) and mass spectrometry (MS) approach to characterize the circadian cardiovascular proteome in 
health and disease. Heart tissue is collected from TAC disease and sham control animals at 6 timepoints 
over the 24-hour light/dark cycle. The cytoplasmic proteome from TAC vs. sham hearts is labelled with 
Cy3 and Cy5 dye, respectively. An internal control consists of pooled samples labelled with Cy2. After 2D-
DIGE protein expression is analyzed with DeCyder. SYPRO Ruby gel for picking spots of interest is 
created. Proteins are excised and identified by MS. Results are validated by Western blot. 
Fig. 2. Experimental design. 
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were visualized with Image Quant TL software. An overlay image of Cy3 and Cy5 scans is 
illustrated in Figure 3A. Proteins that had higher abundance in TAC heart disease vs. sham 
appeared as a red spot. Lower levels in TAC heart disease vs. sham appeared green. Equal 
amounts of protein in TAC heart disease vs. sham were yellow.  
Statistical analysis and quantification of protein expression was achieved by DeCyder 
software (GE Healthcare). In the first step of DeCyder workflow, difference in gel analysis 
(DIA) used a codetection algorithm to detect and match differently labelled samples (Cy2, 
Cy3 and Cy5) within the same gel. It was necessary to define a specific area of interest 
within a gel and then manually confirm that the program detected all the spots within that 
area. Spot intensity corresponding to protein abundance was quantified after background 
subtraction and normalization. The second step termed biological variance analysis (BVA) 
simultaneously analyzed multiple DIGE gels by matching all the spots to a master gel, 
defined by user. Protein expression was compared between gels and statistically verified. 
Based on spot intensity, DeCyder constructed 3D views of relative protein abundance. The 
standardized volume of the peaks was used to calculate fold change.  
In this study, and as shown in Figure 3B, we found three spots (# 596, 615, and 1012) that 
were upregulated in TAC heart disease compared to sham at our sleep-wake transition 
timepoint (ZT23). Spot # 596 had a 1.18 fold change, spot # 615 had a 1.48 fold change, and 
spot # 1012 had 1.77 fold change. To identify the proteins of interest, a pick gel was created 
containing 300 g of unlabelled protein. Glass plates were treated with Bind-Silane  
(-methacryloxypropyltrimethoxysilane) so that the gel was covalently attached to the 
surface. After electrophoresis, proteins were fixed in 10% methanol and 7% acetic acid 
solution for 2 hours, then stained with SYPRO Ruby for 18 hours and destained in 40% 
methanol/10% acetic acid solution for 2 hours. The gel was scanned with a Typhoon 9410 
scanner at 532 nm (670 BP 30 emission filter). Images were uploaded to DeCyder and 
matched to the previous DIGE gel. Unique coordinates for each spot were created using 
position markers. After manual confirmation, an Ettan Spot picker (GE Healthcare) was 
used to excise proteins from the gel.  
3.5 Trypsin digestion and mass spectrometry 
To determine the identification of the proteins in gel spots # 596, 615 and 1012, we used an 
In-Gel Tryptic Digestion Kit (Thermo Scientific) followed by mass spectrometry (MS). 
Trypsin is a serine protease that cleaves the peptide bonds at the carboxyl side of lysine and 
arginine amino acids. Following digestion, tryptic peptide fragments were separated by 
nano-LC which consisted of a trap column (300μm ID) and an analytical column (75 μm ID) 
packed with 5μm, 300Å Zorbax SB C18 beads. A linear binary gradient was used where 
solvent A was 98% H2O:2% CH3CN and 0.1% (v/v) formic acid and solvent B was 2% H2O : 
98% CH3CN and 0.1% (v/v) formic acid. Peptides were eluted over a 2 - 95% solvent B 
gradient for 100 min at a rate of 300 nL/min. The eluant from the nano-LC was coupled to a 
hybrid triple/quadrupole linear ion trap mass spectrometer (QTRAP 4000, ABSciex) 
through a nano-spray ionization source equipped with a 15 μm ID emittor tip. Our 
preferred database for searching was Mascot (http://www.matrixscience.com). This 
database contains information on more than 10 million proteins, with inherent redundancies 
built in since peptides can correspond to more than one protein. Each of the spots generated 
a list of possible protein candidates, and Mascot score and E value helped identify the 
correct match. The molecular weight and pI of the identified protein was comparable to the 
expected molecular weight and pI of the corresponding spot from the 2-DE gel. 
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A) 2D-DIGE image. The gel on the left had proteins purified from TAC (heart disease) labelled with Cy3 
and those from sham heart labelled with Cy5. Gel on the right shows alternatively labelled samples, 
where TAC proteins are labelled with Cy5 and sham with Cy3. Location of the proteins of interest is 
shown with arrows. B) DeCyder computer analysis of three identified protein spots # 596, 615 and 1012. 
Based on standardized abundance these protein spots increased in TAC vs. sham. Expression changes 
are shown by 3D and Graph views. 
Fig. 3. Circadian Cardiovascular Proteomics. 
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3.6 Role of proteins identified in TAC heart disease 
Our laboratory is interested in circadian cardiovascular proteomics to better understand 
molecular processes underlying heart disease and clinical treatments. The TAC upregulated 
spots 519, 615 and 1012 were identified by MS as Succinyl-CoA:3-ketoacid-coenzyme A 
transferase 1, mitochondrial (SCOT), Desmin (DESM), and PDZ and LIM domain protein 1 
(PDLIM1) respectively. Three examples from ZT23 (one hour before lights on, murine sleep-
time) were shown here; other proteins were identified from different times of day or night. 
Figure 4 shows a representative mass spectrum for one of the identified proteins, SCOT 
(spot #519), as well as the number and list of tryptic hits, Mascot score, E-value, and protein 
sequence. Functionally, SCOT is a mitochondrial matrix protein and is the key rate limiting 
enzyme for ketone body metabolism (Fukao et al., 2004; Orii et al., 2008). That it exhibits 
increased expression around sleep time suggests that it plays a role in changing cardiac 
energy sources. The second identified protein, DESMIN (spot # 615) is crucial for muscle 
structure and function, as reviewed in (Paulin & Li, 2004). The third protein, PDLIM1 (spot 
#1012) is a cytoskeletal protein involved in cardiac contractility and cardioprotection, as 
reviewed in (Arias-Loza et al., 2008; Johnsen et al., 2009).  
3.7 Validation: Western blotting 
Candidate circadian biomarkers identified by 2D-DIGE and MS are validated by Western 
blot protein expression analyses using an independent set of cytoplasmic soluble proteins 
from TAC and sham hearts. Proteins (20 g) are separated according to their mass by 12% 
SDS-PAGE and transferred to polyvinylidene fluoride membrane (Bio-Rad) using a semi-
dry transfer apparatus (Bio-Rad). Membranes are blocked for 2 hours at room temperature 
with 5% non-fat dry milk in TBS-T 0.05 % (20 mM Tris Base, 137mM NaCl, 0.05 % Tween 20, 
pH 7.6) and incubated overnight at 4 0C with primary antibodies against SCOT, DESM or 
PDLIM1. The antibodies are diluted according to the manufacturer’s instructions. Anti-actin 
antibody (1:40000, Milipore) is used as a loading control. Immunoreactive protein bands are 
visualized with horseradish peroxidise-conjugated secondary antibodies (1:5000, Sigma) and 
ECLplus reagent (GE Healthcare). Blots are scanned using Storm 860 molecular imager (GE 
Healthcare) and protein expression is quantified by Image J software (NIH). Expression 
levels of SCOT, DESM and PDLIM1 in TAC samples at ZT23 are compared to sham, thus 
independently validating 2D-DIGE approach. Validating the candidate proteins/biomarkers 
in human samples will increase their significance and is key to translational applications.  
4. Circadian proteomes in other body organs 
Our time-of-day circadian approach led to discovery of SCOT, DESMIN, and PDLIM which 
were upregulated in TAC cardiac hypertrophy at sleep time. Other groups have also met with 
success investigating circadian proteomics in different tissues and clinical paradigms. A 
summary of identified circadian proteomes is shown in Table 1. The first identification of a 
circadian proteome was reported by Reddy and colleagues (Reddy et al., 2006), using a 2D-
DIGE/MS approach to study murine liver. Mice were entrained to 12:12 L:D cycles, then placed 
in constant darkness (12:12 D:D) and sacrificed at 6 consecutive time-points 4 hours apart. It was 
observed that 135 (21%) out of 642 detected protein spots rhythmically cycled over the 24-hour 
period. Many of the newly identified circadian proteins were key rate limiting enzymes 
including ketohexokinase, succinate dehydrogenase 1, aldolase 2, enolase 1/aconitase 2, 
carbamoyl phosphate synthetase 1, CPS1, arginosuccinate synthetase 1, and arginase 1. 
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Tissue Methods Proteins with circadian 
expression pattern 
Function Reference 
Liver 
 
CD1 mice 
Mice were 
entrained under 
12:12 L:D and then 
transferred to 
12:12 D:D 
(constant 
darkness). Liver 
tissue was 
collected every 4-h 
over 24-h starting 
at CT 0 
(n = 3/ time point) 
 
2D-DIGE 
MALDI-TOF MS 
LC MS/MS 
Arginosuccinate 
synthetase 1 (ASS1) 
Urea cycle (Reddy et al., 
2006) 
Carbamoyl phosphate 
synthetase 1 (CPS1) 
Urea cycle 
Arginase 1 (ARG1) 
Ketohexokinase (KHK)  
Fructose metabolism Succinate dehydrogenase 
1 (SDH1) 
Aldolase 2 (ALDO2) Glycolysis 
Enolase 1 (ENO1) 
Aconitase 2 (ACO2) Kreb’s cycle 
Pineal gland 
 
Wistar rats 
Rats were 
entrained under 
12:12 L:D. Pineal 
glands were 
collected at ZT6 (6 
hours after lights 
on) and ZT18 (6 
hours after lights 
off) 
(n = 8/ time point) 
 
 
2D-PAGE 
MALDI-TOF MS 
Dark period (rodent wake time) (Moller, 
Sparre et al. 
2007) 
Alpha enolase  
Glycolysis pathway Gamma enolase 
Vimentin Morphogenesis 
Creatine kinase, B chain Energy transduction 
Guanine deaminase Purine catabolism 
Peptidyl-prolyl cis-trans 
isomerase A 
Protein folding 
Annexin A2 and A5 Ca2+-regulated 
membrane-binding 
Light period (rodent sleep time) 
Malate Dehydrogenase Krebs cycle 
Citrate synthase 
Triosephosphate 
Isomerise 
Ubiquinolcytochrome c 
reductase core protein I 
Mitochondrial electron 
transport 
RNA recognition motif Processing of pre-mRNAs 
Chaperonin containing 
TCP1 
Chaperone, signal 
transduction 
ER protein ERp29 
precursor(Erp31) 
Transitional endoplasmic 
reticulum ATPase 
Vesicle budding from the 
endoplasmic 
reticulum 
Complement C3 
Precursor 
Activation of the 
complement system 
Phosphoserine 
phosphatise 
Biosynthesis of serine 
from carbohydrates 
Contrapsin-like protease 
inhibitor 1 and 3 
precursor 
Protein metabolism 
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Tissue Methods Proteins with circadian 
expression pattern 
Function Reference 
Retina 
 
C57BL/6 mice 
Mice were 
entrained under 
12:12 L:D and 
transferred to 
12:12 D:D. Retinal 
tissue was 
collected every 6-h 
over 24-h starting 
at CT 2 
(n = 5/ time point) 
 
2D-PAGE 
MALDI-TOF MS 
N-ethylmaleimide-
sensitive fusion protein 
Vesicle transport 
 
(Tsuji, Hirota 
et al. 2007) 
Charged Multivesicular 
body protein 4b 
Reticulocalbin-2 
precursor 
Calcium binding 
 
Photoreceptor adaptation, 
gating of photic input 
Calbindin D28 
Heterogeneous 
ribonucleoprotein A/B 
RNA-binding 
T-complex 1 subunit delta Protein folding, 
phototransduction, 
morphological changes 
Leukotriene A4 hydrolase Metabolism 
Proteasome subunit alpha 
type 1 
Protein degradation 
SCN releasate 
 
Long-
Evans/BluGill 
rats 
Rats were 
entrained under 
12:12 L:D and 
transferred to 
12:12 D:D. 
Samples were 
taken every 4-h 
over 24-h starting 
at CT 0 
 
LC MALDI-TOF 
MS 
LC MS/MS 
Angiotensin I (Hatcher et 
al., 2008) Arginine vasopressinb 
Proenkephalin 219–229 
Galanin 
Neurokinin-B 
Neurotensin 
POMC, melanotropin  
PEN 
Big LEN 
Little SAAS 
Somatostatin-14b 
proSomatostatin 89-100 
Substance P 
Thymosin -4 
Urine 
 
Tau mutant 
hamsters 
Hamsters 
entrained under 
14:10 L:D cycle. 
 
SDS-PAGE 
LC MS/MS 
Cytochrome C (CYCS) Apoptosis (Martino et 
al., 2008) 
Blood 
C57Bl/6 
Mice entrained to 
12:12 L:D cycle 
SELDI 
Fingerprinting assay Proof of concept that de-
novo proteins cycle in the 
blood, and that the daily 
rhythmic variation 
changes in heart disease 
Ref Martino 
same one as 
below 
Blood 
 
C57BL/6 mice 
Mice entrained 
under 12:12 L:D 
cycle. Samples 
collected every 4 
hours, starting at 
ZT 23 (n = 3/ time 
point) 
 
SDS-PAGE 
LC MS/MS 
Transthyretin 
 
Transports thyroxin (T4) 
and retinol (vitamin A) 
(Martino, 
Tata et al. 
2007) Apolipoprotein A1 
precursor 
Lipid and cholesterol 
regulation 
Apolipoprotein E 
precursor 
Apolipoprotein J 
Plasminogen Plasmin formation 
Complement C3 
precursor 
Activation of compliment 
system 
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Tissue Methods Proteins with circadian 
expression pattern 
Function Reference 
Blood metabo-
lome 
 
C57BL/6 and 
CBA/N mice 
Mice entrained 
under 12:12 L:D 
cycles, then 
transferred to 
either 12:12L:D or 
12:12 D:D. Blood 
collected in fasting 
animals over 24-h 
starting at ZT 4 or 
CT 4 
 
LC-MS 
CE-MS 
Trimethylamine N-oxide (Minami et 
al., 2009) Glutamine 2-Aminobutyrate 
Cytidine 
Sarcosine 
Carnitine 
Valine 
Tryptophan 
4-Guanidinobutyrate 
Isoleucine 
3-Methylhistidine 
Leucine 
Proline 
Guanidoacetate 
1-Methylnicotinamide 
Citrulline 
Creatinine 
Glycine 
Methionine sulfoxide 
a-Aminoadipate 
Methionine 
Phenylalanine 
N,N-Dimethylglycine 
Thr 13C 
Threonine 
Ornithine 
Hydroxyproline 
Creatine 
Corticosterone 
lysophosphatidylcoline 
Table 1. Circadian proteomes. 
The circadian proteome in the rat pineal gland was identified using 2D-PAGE, silver stain 
and tandem mass spectrometry (MS/MS) (Moller et al., 2007). In this study, rats were 
entrained to 12:12 L:D cycle. Pineal glands were collected at two timepoints: ZT06 which is 6 
hours after lights on (light phase, rats asleep) and ZT18 which is 6 hours after lights off 
(dark phase, rats awake). A total of 1737 pineal gland proteins were detected, 35 showed 
greater abundance during sleep time and 25 during wake time. Proteins upregulated during 
wake time were involved in glycolysis (alpha- and gamma-enolase), morphogenesis 
(vimentin), energy transduction (Creatine kinase), purine catabolism (guanine deaminase), 
protein folding (peptidyl-prolyl cis–trans isomerase A), and Ca2+-dependent membrane 
binding (annexin A2, annexin A5). Proteins with increased abundance during sleep mapped 
to the Krebs cycle (malate dehydrogenase, citrate synthase, triosephosphate isomerise), 
mitochondrial electron transport (ubiquinol-cytochrome c reductase core protein 1), RNA 
binding and processing (RNA recognition motif), protein folding (chaperone-containing 
TCP1, ER protein ERp29 precursor), cell transport (transitional ER ATPase), complement 
(C3 precursor), and metabolism (phosphoserine phosphotase, contrapsin-like protease 
inhibitor 1 and 3 precursors).  
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The circadian proteome of the mouse retina was characterized by 2D-PAGE and Coomassie 
Brilliant stain (Tsuji et al., 2007). C57Bl/6 mice were entrained at 12:12 L:D cycle, then placed 
in constant darkness (12:12 D:D) and sacrificed on the fourth day at 4 timepoints: CT2, CT8, 
CT14, and CT20. CT2 corresponded to subjective dawn and CT12 to subjective dusk. A total 
of 415 protein spots were detected and 11 exhibited circadian rhythms. The cycling proteins 
were important in vesicular transport (N-ethylmaleimide-sensitive fusion protein, charged 
multivesicular body protein 4b), calcium-binding (calbindin D28, reticulocalbin-2 
precursor), RNA-binding (heterogeneous ribonucleoprotein A/B), protein folding  
(T-complex 1 delta), metabolism (leukotriene A4 hydrolase), and protein degradation 
(proteasome subunit alpha1). 
The circadian peptidome released from rat hypothalamic SCN was characterized using a 
gel-free approach (Hatcher et al., 2008). Long-Evans/BluGill rats were entrained to 12:12 
L:D and then transferred to constant darkness. Animals were sacrificed during subjective 
day-time (CT 0-12) and brain slices containing SCN and optic nerve were prepared. SCN 
releasates were obtained from extracellular fluid with pipettes containing solid-phase 
extraction material or from the SCN itself with micrometer-sized beads with solid-phase 
extraction material. Samples of releasate were collected at the beginning and end of CT 0–4, 
4–8, 8–12, 12–16, 16–20, and 20–24 intervals and analyzed with MALDI TOF MS. Identified 
peptides were independently verified with LC-MS/MS. Arginine vasopressin showed a 
robust circadian rhythm with a peak during sleep time. Other identified peptides were 
angiotensin I, arginine vasopressinb, proenkephalin, galanin, neurokinin-B, neurotensin, 
melanotropin , PEN, big LEN, little SAAS, somatostatin-14b, proSomatostatin, substance  
P and thymosin -4. Interestingly, this study also detected previously unknown peptides, 
which prompted further investigation of their biological role. 
5. The circadian proteome helps to understand disease and identify new 
biomarkers 
Disturbances of the circadian rhythm, such as might occur in humans in shift work or sleep 
disorders, can affect many physiologic processes (e.g. circadian rhythms of heart rate, body 
temperature, sympathetic nervous activity, chemical, inflammatory, and metabolic 
processes). The proteome should characteristically change as well, revealing de novo 
biomarkers. We investigated this using a +/tau hamster model bearing a mutation in the 
core circadian clockwork protein casein kinase 1 epsilon (Martino et al., 2008). The circadian 
rhythm disruption in these animals etiologically caused heart and kidney disease. The 
animals exhibited profound proteinuria. To detect proteomic changes, urine samples 
collected from +/tau vs. controls were analyzed on 10-20% tricine gels stained with 
Coomassie dye. Bands were excised from the gel, trypsin digested, subjected to MS/MS on a 
LCQ DECA XP ion trap, and analyzed using Sequest. Protein identification was validated 
by Western blot. As shown in Table 1, a ~15 kDa protein band, appearing only in the urine 
of the +/tau animals, was identified by MS as cytochrome c, a biomarker of cellular 
apoptosis. Apoptosis was confirmed in the renal tissues of +/tau mutants by terminal 
uridine deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) staining. Thus by 
using circadian approaches, a novel biomarker of renal disease was discovered. This was a 
particularly exciting discovery as there are notably very few biomarkers of developing renal 
disease. For example, a usual biomarker for kidney disease is creatinine, however, this 
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represents just chemical waste generated from muscle metabolism and is only an indirect 
marker of renal function. Here we identified a direct indicator of early and ongoing tissue 
damage, by investigating circadian proteome expression. This marker is easily obtained by 
collecting urine samples, thus making it potentially ideal for point-of-care or routine 
diagnostics. Additional examples of circadian-based biomarkers, including many 
fundamental to human health and disease, are described below. 
6. Circadian biomarkers in blood 
Circadian proteomics can be used for discovery of de-novo blood biomarkers of  
heart disease. Established cardiovascular factors (e.g. hypertension, smoking, diabetes) do 
not fully explain the risk for heart disease, and there is substantial interest in the 
development of new biomarkers to identify persons at risk and who may be targeted for 
preventative measures. In those with heart disease, biomarkers are in demand to  
help track disease progression and aid physicians in better treating their patients. 
Although a number of strategies are currently used to identify biomarkers, there have 
been very few clinical advances, and thus new approaches such as circadian proteomics 
are warranted.  
As an example, we recently investigated diurnal proteome cycling in murine blood 
(Martino et al., 2007). Blood was the preferred tissue for biomedical investigation because 
of its ease of accessibility and minimal invasiveness for sampling. As shown in Table 1, 
the first approach was proof of concept and used surface-enhanced laser desorption 
ionization (SELDI) MS. Only proteins retained on ion exchange solid phase 
chromatographic surfaces (or chips) were examined; substances with other biochemical 
properties remain open to future investigation. Expression profiles were collected over a 
wide mass range; those of lower molecular weight (1-10 kDa range) classically contained 
bioactive peptides, while those in the midrange (10-50 kDa) and larger (>50 kDa) reflected 
peptides/proteins involved in cell structural and functional processes. With SELDI MS we 
essentially created a fingerprint of blood protein expression over the 24-hour time, from 
which one could then quantify, statistically analyze and graph data to visualize daily 
protein rhythms.  
Since one of the drawbacks of SELDI MS was a relative inability to further identify the 
fingerprint proteins, the diurnal blood proteome was also characterized following 
prefractionation on column chromatography with an ion exchange resin (Martino et al., 
2007). As shown in Table 1, proteins comprising effluent, salt elution, and bead retentive 
fractions were visualized by SDS-PAGE and silver stain. Protein bands that exhibited cyclic 
variation over 24 hours were excised, trypsin digested, and then injected by electro spray 
ionization (ESI) into a LCQ DECA XP ion trap. Proteins were identified by comparison 
searching molecular mass against murine databases. Many of the identified blood proteins 
with diurnal expression linked to cycles in physiology were those released from liver, such 
as transthyretin, apolipoprotein A1 precursor, apolipoprotein E precursor, apolipoprotein J, 
plasminogen and complement C3 precursor. Ultimately, comparing daily rhythms in sera 
from healthy individuals vs. heart disease patients would allow for the creation of new 
biomarker profiles and discovery platforms. 
Another study examining diurnal biomarkers in blood measured 24-hour profiles of small 
chemical substances (peptides, amino acids, hormones) (Minami et al., 2009). As shown in 
Table 1, blood was drawn every 4 hours over the 24-hour period from CBA mice maintained  
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A) Representative mass spectrum of the SCOT peptide: RGGHVNLTMLGAMQVSKY. B) A total of  
24 peptides were identified, corresponding to 13 unique sequences. The Mascot score is 150, E-value is 
4.0 ×10-21. C) Identified peptides and their corresponding match to the SCOT protein sequence. 
Fig. 4. MS based identification of Succinyl-CoA:3-ketoacid-coenzyme A transferase 1, 
mitochondrial (SCOT). 
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under L:D or D:D conditions and LC-MS analysis was performed that led to the detection 
of 176 negative and 142 positive ion peaks. Importantly, in transgenic murine model of 
clock disruption (Cry1-/- and Cry2-/-), expression of these metabolites was altered, 
suggesting that they were controlled by the clock mechanism. The authors demonstrated 
that their metabolite timetable could be used to accurately determine body time in mice 
with different genetic background, age, sex and feeding regime. The overall purpose of 
doing this was to create maps of body time, which could be applied clinically to optimize 
understanding of disease or determine the best times for administering drugs and 
therapies. 
7. Circadian rhythms in neuro/hormone biomarkers 
Long before protein cycling was even discovered, it was already known that some key 
neuroendocrine hormones important to the heart had daily rhythmic patterns of expression. 
Cycling of many of these hormones drives the protein rhythms we observe in normal heart 
and other tissues, and the changes that occur in disease.  Further details are described below 
and in Figure 5 and Table 2.  
7.1 Sleep-time hormones 
The first example is melatonin, and its expression in humans is elevated in the dark  
but suppressed by light (thus it is sometimes called the “hormone of darkness”) 
(Brzezinski, 1997). It has a cardioprotective effect through antioxidant and anti-
inflammatory activity, reviewed by (Tengattini et al., 2008). It is a useful circadian 
biomarker of heart disease. Nocturnal melatonin levels were low in patients with acute 
myocardial infarction (MI) vs. healthy controls within the first 24 hours after hospital 
admission (Dominguez-Rodriguez et al., 2002). Also, patients with ST-segment MI who 
developed adverse events during follow-up had significantly lower nocturnal melatonin 
levels than patients without the events (Dominguez-Rodriguez et al., 2006). In another 
study it was revealed that nocturnal melatonin levels were reduced in patients with 
cardiac syndrome X vs. controls (Altun et al., 2002). Second, the renin-angiotensin-
aldosterone system (RAAS) also exhibits circadian rhythm. Aldosterone produced by the 
adrenal cortex regulates Na+ and K+ homeostasis. Aldosterone plasma levels peak during 
sleep time (11:00 P.M. – 7:00 A.M.) (Charloux et al., 1999). As a biomarker of heart disease, 
it has been reported that while normal subjects showed an 81% decrease during the wake 
period, there was only a 40% decrease in low renin hypertensive patients (Grim et al., 
1974). Similarly, plasma renin activity (PRA) cycles in healthy subjects with peak activity 
during sleep (Charloux et al., 1999). Patients with hypertensive heart disease exhibited a 
greater increase in PRA during sleep-time as compared to normotensive patients (Tuck et 
al., 1985).  
Finally, growth hormone secretion by the anterior pituitary gland is pulsatile and has a 
circadian rhythm with the highest peak occurring at midnight (Surya et al., 2006). Growth 
hormone is involved in regulation of cardiac metabolism and contractility, reviewed by 
(Volterrani et al., 2000). In some heart failure patients (New York Heart Association classes 
I-III) there is a loss of circadian rhythm and overall reduction of growth hormone secretion 
(Duncan et al., 2003).  
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Left; Melatonin, aldosterone, plasma renin activity, growth hormone peak during sleep time. Right; 
cortisol, epinephrine, vasoactive intestinal peptide peak during wake time. X-axis: white bar = light 
period, black bar = dark. Rhythms illustrated here are based on the references listed in Table 2. 
Fig. 5. Dirunal cycling of hormones in blood. 
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Hormone Selective 
function(s) 
relevant to the 
cardiovascular 
system 
Hormone Cycling References 
In healthy 
humans 
Altered cycling in 
specified 
cardiovascular 
disease 
* Used in Figure 5 
§ Heart disease 
# Additional 
references 
Melatonin Antioxidant, 
circadian 
entrainment 
Nocturnal peak 
in blood (in the 
dark) 
 
Secretion is 
suppressed by 
light and 
activated in the 
dark 
Nocturnal decrease 
observed within the 
first 24h period in 
patients with 
myocardial infarct 
(MI) 
 
Low levels of 
melatonin  correlate 
with adverse events 
during follow up in 
ST-segment MI 
patients 
 
Nocturnal decrease 
in patients with 
cardiac syndrome X 
vs. healthy controls 
* (Brzezinski, 
1997) 
# (Claustrat et al., 
1986) 
# (Follenius et al., 
1995) 
§ (Dominguez-
Rodriguez et al., 
2006) 
§ (Dominguez-
Rodriguez et al., 
2002) 
§ (Altun et al., 
2002) 
Aldosterone Regulates 
Na+/K+ 
homeostasis, 
blood pressure 
Peak serum 
levels  during 
sleep time 
Does not decrease 
normally during the 
day in low renin 
hypertensive patients 
vs. healthy controls 
* (Charloux et al., 
1999) 
# (Katz et al., 
1975) 
# (Lightman et al., 
1981) 
§ (Grim et al., 
1974) 
Plasma Renin 
Activity 
Regulates blood 
pressure 
Significantly 
higher plasma 
activity during 
sleep time 
Significantly 
upregulated only at 
night in some 
patients with 
essential 
hypertension 
* (Charloux et al., 
1999) 
# (Katz et al., 
1975) 
§ (Tuck et al., 
1985) 
Growth 
Hormone 
Affects 
metabolism and 
contractility 
Nocturnal 
plasma peak 
 
Exhibits pulsatile 
expression 
Overall decrease and 
loss of circadian 
rhythm in some 
patients with chronic 
heart failure (NY 
Heart Association 
classes I-III) 
* (Surya et al., 
2006) 
# (Takahashi et 
al., 1968) 
# (Hartman et al., 
1991) 
§ (Duncan et al., 
2003) 
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Hormone Selective 
function(s) 
relevant to the 
cardiovascular 
system 
Hormone Cycling References 
In healthy 
humans 
Altered cycling in 
specified 
cardiovascular 
disease 
* Used in Figure 5 
§ Heart disease 
# Additional 
references 
Cortisol Regulates blood 
sugar levels, 
increases blood 
pressure 
Serum levels 
peak around 
wake-time 
Peaks at 4:00 A.M. in 
some low renin 
hypertensive patients 
* (Charloux et al., 
1999) 
* (Lightman et al., 
1981) 
# (Lockinger et al., 
2004) 
# (Cugini et al., 
1991) 
§ (Grim et al., 
1974) 
Epinephrine Increases heart 
rate and blood 
pressure 
 
Mediates 
sympathetic 
response 
Plasma levels 
peak during 
wake time 
Nocturnal increase in 
some patients with 
obstructive sleep 
apnea vs. healthy 
controls 
* (Linsell et al., 
1985) 
# (Scheer et al., 
2009) 
# (Akerstedt & 
Froberg, 1979) 
§ (Alonso-
Fernandez et al., 
2005) 
Vasoactive 
intestinal 
peptide 
Regulates 
vasodilation, 
heart rate, force 
of contraction 
Plasma peak 
before sleep 
(20:00), trough at 
night (0:00) 
Circadian rhythm is 
lost in patients with 
orthotopic heart 
transplant 
* (Cugini et al., 
1991) 
# (Cugini et al., 
1992) 
§ (Cugini et al., 
1993) 
Table 2. Circadian rhythms in neuro/hormones in humans 
7.2 Wake time hormones 
Cortisol exhibits diurnal variation with serum levels peaking early in the morning around 
wake time and troughing late in the evening (Charloux et al., 1999; Lightman et al., 1981). It 
may also be a useful biomarker or mediator of disease as plasma cortisol peaks earlier at 
4:00 A.M. in some low renin hypertensive patients, as compared to 8:00 A.M. in normal 
controls (Grim et al., 1974). Epinephrine stimulates sympathetic activity including in the 
cardiovascular system. It exhibits a robust endogenous circadian rhythm that peaks during 
wake time (Linsell et al., 1985), and this expression changes in obstructive sleep apnea heart 
failure patients, in which there is increased nocturnal sympathetic tone (Alonso-Fernandez 
et al., 2005; Bradley & Floras, 2009). Lastly, vasoactive intestinal peptide affects vasodilation, 
heart rate and force of contraction, reviewed by (Henning & Sawmiller, 2001). It has a 
circadian rhythm with a peak before sleep time (20:00) and a trough later at night (0:00) 
(Cugini et al., 1991). The rhythm of this peptide is lost in patients with orthotopic heart 
transplant (Cugini et al., 1993). 
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8. Clinical translation 
Discovery of the circadian cardiovascular proteome and it’s endogenous drivers provides a 
new understanding of cardiovascular health and disease, where time is a new paradigm of 
functional significance. Proteomic biomarkers can be easily implemented with ELISA-type 
point-of-care diagnostic platforms that could be routinely applied in physician offices, or 
even potentially in the consumer’s home. One of the practical applications of cardiovascular 
circadian proteomics is chronotherapy, which requires easily accessible markers of body 
time for optimizing the timing of drug treatments. For example, we recently demonstrated 
that the efficacy of treatment with the angiotensin converting enzyme inhibitor (ACEi) 
captopril exhibits a diurnal pattern, consistent with the diurnal variation in ACE expression 
(Martino et al., 2011). ACEi are common medications given to cardiovascular patients with 
hypertension, after a myocardial infarction or with heart failure. We found that drug 
administration at sleep-time improved heart function, but wake-time did not differ from 
placebo. This approach can be used in other diseases such as cancer (Hrushesky & 
Bjarnason, 1993; Innominato et al., 2010) and neuroendocrine disorders (Chung et al., 2011) 
as well. 
9. Conclusion 
Circadian cardiovascular proteomics is an important new area of research that provides an 
excellent opportunity to elucidate molecular processes that underlie our health and disease 
across the 24-hour light/dark period. At this early stage, temporal analysis of the proteome 
in cardiovascular tissues (i.e. heart or blood) of experimental animal models reveals 
remarkable 24-hour variations in protein abundances. Diurnal protein profiles differ 
remarkably between health and disease. Characterization of these proteins is the key to 
understanding normal body physiology as well as providing new diagnostic capabilities, 
and new approaches to treatment by aiding in the design of personalized therapeutics. 
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